XOMA Dividend

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von XOMA in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von XOMA gestiegen sind.

Dividend Yield vs Market

XOMA Dividend Yield vs Market

How does XOMA dividend yield compare to the market?
Segment	Dividend Yield
Company (XOMA)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.8%
Analyst forecast in 3 Years (XOMA)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von XOMA im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von XOMA im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Earnings Payout to Shareholders

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von XOMA, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da XOMA keine Ausschüttungen gemeldet hat.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

XOMA Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 58%

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 33%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Investor sentiment deteriorated over the past week

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

Investor sentiment improved over the past week

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 12%

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$62.50

Now 24% undervalued

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Now 20% undervalued

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to US$49.00

Price target decreased to US$46.00

Investor sentiment deteriorated over the past week

Xoma Gets The Spotlight

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall to US$9.98m

Consensus EPS estimates increase to -US$0.83

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

Price target increased to US$52.33

CEO & Director recently sold US$303k worth of stock

Investor sentiment improved over the past week

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Consensus EPS estimates fall to -US$1.00

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

XOMA EPS misses by $0.55, misses on revenue

XOMA gets milestone payment from Janssen Biotech

Investor sentiment improved over the past week

Key Executive exercised options to buy US$212k worth of stock.

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Consensus revenue estimates increase to US$17.1m

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Full year 2020 earnings released: EPS US$0.82 (vs US$0.23 loss in FY 2019)

Revenue and earnings beat expectations

Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

Analysts increase EPS estimates to US$0.41

XOMA: A Royalty Aggregator To Watch

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?